ANDA 76914, held by Graviti Pharmaceuticals. Acetaminophen; Tramadol Hydrochloride.
As of Nov 21, 2026, ANDA 76914 (Tramadol Hydrochloride and Acetaminophen), held by Graviti Pharmaceuticals, was first approved by FDA on Jul 26, 2006, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 26, 2006 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tramadol Hydrochloride and Acetaminophen325MG;37.5MG · tablet;oral | Acetaminophen; Tramadol Hydrochloride | Discontinued |
| Jun 18, 2026 | Supplement 11REMS | Approved | None posted |
| Dec 29, 2025 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Supplement 9REMS | Approved | None posted |
| Dec 19, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Dec 18, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 18, 2018 | Supplement 6REMS | Approved | None posted |
| Jun 16, 2017 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 26, 2006 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters